Health economic evaluation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma: a systematic review

Table 1 Basic characteristics of included studies

Included research	Region	Research type	Study method	Study perspective	Study population	Intervention technique	Control comparator technique	Outcome indicator
Hayeon Kim [17]	USA	CUA^f	Markov model	Payer	Unresectable CRC liver metastases	SBRT^a	RFA^b	ICER^c
Leung [18]	Taiwan	CUA	Markov model	Payer	Advanced HCC	Sorafenib	SBRT	ICER
Pollom [19]	USA	CUA	Markov model	Social	Inoperable localized HCC	SBRT	RFA	ICER
Leung [20]	Taiwan	CUA	Markov model	Payer	Inoperable advanced HCC	Proton beam therapy	SBRT	ICER, NMBs^c
Parikh [21]	USA	CEA^g	Retrospective study	Payer	Early stage HCC	SBRT	RFA	ICER^e

^a Stereotactic body radiotherapy; ^b radiofrequency ablation; ^c incremental cost effect ratio; ^d net monetary benefits; ^e life-year gained instead of quality life-year gained. ^f cost-utility analysis;^g cost-effectiveness analysis

ISSN: 1478-7547